13 days ago
BMY
AnalystsAndrew BaumAndrew Baum's Stock Forecasts
AnalystsAndrew Baum
Analyst Ranking
Top 19%
#956 out of 5116 analysts
Average Return
+18.21%
Win Rate
74%20 out of 27
Risk vs Reward
Poor
Good
Andrew Baum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +145.62% | $318.43 | $782.12 | 2023-03-03 - 2024-03-01 | Strong Buy |
Eli Lilly & CoLLY | +81.04% | $453.59 | $821.19 | 2023-07-26 - 2024-07-25 | Strong Buy |
Eli Lilly & CoLLY | +57.66% | $576.65 | $909.15 | 2023-10-23 - 2024-10-22 | Strong Buy |
Eli Lilly & CoLLY | +45.16% | $230.36 | $334.38 | 2021-09-29 - 2022-09-28 | Strong Buy |
Royalty Pharma PLCRPRX | +38.26% | $26.95 | $37.26 | 2024-10-25 - 2025-10-24 | Strong Buy |
Andrew Baum Analyst Color
Get additional color on Andrew Baum's coverage of popular stocks
10 months ago
MRK
a year ago
ABBV
2 years ago
LLY
2 years ago
LLY
2 years ago
PFE
2 years ago
LLY
3 years ago
MRK
Andrew Baum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Bristol Myers Squibb CoBMY | 9 | Hold | $45.00 | -8.54% | Maintains | 13 days ago |
Pfizer IncPFE | 6 | Hold | $26.00 | +1.01% | Maintains | 4 months ago |
Merck & Co IncMRK | 9 | Strong Buy | $115.00 | +9.70% | Maintains | 10 months ago |
Royalty Pharma PLCRPRX | 2 | Strong Buy | $40.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 5 | Strong Buy | $215.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 5 | Strong Buy | $895.00 | N/A | Maintains | 2 years ago |
AlvotechALVO | 3 | Hold | $10.00 | N/A | Upgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.